Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor James Wason.

Newcastle AuthorsTitleYearFull text
Dr Haiyan Zheng
Professor James Wason
Bayesian sample size determination using commensurate priors to leverage preexperimental data2022
Dr Haiyan Zheng
Professor James Wason
Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy2022
Dr Guy Taylor
Andy Shaw
Kieran Smith
Professor James Wason
Professor Emma Stevenson
et al.
Capturing the real-world benefit of residual β-cell function during clinically important time-periods in established Type 1 diabetes2022
Dr Michael Grayling
Professor James Wason
Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials2022
Professor James Wason
Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis2022
Professor James Wason
Discussion on “Adaptive enrichment designs with a continuous biomarker” by Nigel Stallard2022
Dr Michael Grayling
Professor Rakesh Heer
Professor James Wason
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials2022
Dr Michael Grayling
Professor James Wason
Response adaptive intervention allocation in stepped-wedge cluster randomized trials2022
Dr Jessica Barrett
Professor James Wason
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints2022
Dr Theophile Bigirumurame
Germain Uwimpuhwe
Professor James Wason
Sequential multiple assignment randomized trial studies should report all key components: a systematic review2022
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data2022
Aritra Mukherjee
Professor James Wason
Dr Michael Grayling
When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay2022
Dr Dennis Lendrem
Dr Jessica Tarn
Professor James Wason
Professor Fai Ng
Why stratification is important in primary Sjögren’s syndrome2022
Dr Michael Grayling
Professor James Wason
A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials2021
Professor James Wason
A two-stage drop-the-losers design for time-to-event outcome using a historical control arm2021
Dr Ankur Mukherjee
Dr Michael Grayling
Professor James Wason
Adaptive designs: Benefits and cautions for neurosurgery trials2021
Helen Mossop
Dr Michael Grayling
Professor James Wason
Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials2021
Professor James Wason
Bayesian design and analysis of external pilot trials for complex interventions2021
Professor James Wason
Controlling type I error rates in multi‐arm clinical trials: A case for the false discovery rate2021
Dr Nina Wilson
Rebecca Maier
Professor Helen Hancock
Professor James Wason
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project2021
Dr Svetlana Cherlin
Professor James Wason
Developing a predictive signature for two trial endpoints using the cross-validated risk scores method2021
Professor James Wason
Employing a latent variable framework to improve efficiency in composite endpoint analysis2021
Dr Michael Grayling
Professor James Wason
Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables2021
Professor James Wason
Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients2021
Dr Michael Grayling
Professor James Wason
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial2021
Dr Michael Grayling
Dr Theophile Bigirumurame
Dr Svetlana Cherlin
Luke Ouma
Dr Haiyan Zheng
et al.
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential2021
Dr Svetlana Cherlin
Professor James Wason
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial2021
Professor James Wason
Prediction of Dementia Using Diffusion Tensor MRI Measures - the OPTIMAL Collaboration2021
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
Dr Elena Nikiphorou
Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?2021
Dr Alexis Collins
Dr Dennis Lendrem
Professor James Wason
Dr Jessica Tarn
Dr Nadia Howard-Tripp
et al.
Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine2021
Professor James Wason
Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats2021
Luke Ouma
Dr Michael Grayling
Dr Haiyan Zheng
Professor James Wason
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods2021
Professor James Wason
Two-stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials2021
Professor James Wason
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints2020
Dr Michael Grayling
Professor James Wason
A web application for the design of multi-arm clinical trials2020
Professor James Wason
Analysis of responder-based endpoints: improving power through utilising continuous components2020
Professor Miles Witham
Professor James Wason
Dr Richard Dodds
Professor Avan Sayer
Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures2020
Professor Miles Witham
Ella Anderson
Kimberley Down
Rebecca Maier
Dr Gary Nestor
et al.
Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process2020
Dr Svetlana Cherlin
Professor James Wason
Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores2020
Professor James Wason
Dr Faye Williamson
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-192020
Professor James Wason
Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold.2020
Professor Miles Witham
Ella Anderson
Kimberley Down
Rebecca Maier
Dr Gary Nestor
et al.
Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project2020
Professor James Wason
Graphical approaches for the control of generalized error rates2020
Professor James Wason
Imaging breast cancer using hyperpolarized carbon-13 MRI2020
Professor James Wason
Including non-concurrent control patients in the analysis of platform trials: is it worth it?2020
Professor James Wason
Mentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation2020
Christopher Bojke
Professor James Wason
Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial2020
Dr David Cottrell
Professor James Wason
Multisystemic therapy compared with management as usual for adolescents at risk of offending: the START II RCT2020
Dr David Cottrell
Professor James Wason
Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial2020
Professor James Wason
Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals2020
Professor James Wason
Simple MRI scores aids prediction of dementia in cerebral small vessel disease2020
Professor James Wason
The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design2020
Dr Michael Grayling
Professor James Wason
Admissible multiarm stepped-wedge cluster randomized trial designs2019
Professor James Wason
Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study2019
Professor James Wason
Familywise error control in multi-armed response-adaptive trials2019
Professor James Wason
Overestimated treatment effects in randomised phase II trials: What's up doctor?2019
Professor James Wason
To add or not to add a new treatment arm to a multi-arm study: a decision-theoretic framework2019
Dr Michael Grayling
Professor James Wason
Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies2019
Professor James Wason
When to keep it simple - adaptive designs are not always useful2019
Professor James Wason
Adaptive designs in clinical trials: why use them, and how to run and report them2018
Dr Michael Grayling
Professor James Wason
An optimised multi-arm multi-stage clinical trial design for unknown variance2018
Dr Michael Grayling
Professor James Wason
Blinded and unblinded sample size re-estimation in crossover trials balanced for period2018
Dr Michael Grayling
Professor James Wason
Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials2018
Dr Michael Grayling
Professor James Wason
Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables2018
Dr Michael Grayling
Professor James Wason
Group sequential crossover trial designs with strong control of the familywise error rate2018
Professor James Wason
Improving the analysis of composite endpoints in rare disease trials2018
Professor James Wason
Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study2018
Dr David Cottrell
Professor James Wason
Multisystemic Therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a randomised controlled pragmatic effectiveness superiority trial2018
Professor James Wason
Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?2018
Professor James Wason
A multi-stage drop-the-losers design for multi-arm clinical trials2017
Dr Michael Grayling
Professor James Wason
Group sequential designs for stepped-wedge cluster randomised trials2017
Dr Ross Maxwell
Professor James Wason
Imaging biomarker roadmap for cancer studies2017
Professor James Wason
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements2017
Dr Michael Grayling
Professor James Wason
Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features2017
Professor James Wason
The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI2017
Professor James Wason
Two-stage phase II oncology designs using short-term endpoints for early stopping2017
Professor James Wason
A review of statistical designs for improving the efficiency of phase II studies in oncology2016
Professor James Wason
An adaptive design for updating the threshold value of a continuous biomarker2016
Professor James Wason
HLA associations in South Asian multiple sclerosis2016
Professor James Wason
Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial2016
Professor James Wason
Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method2016
Professor James Wason
Some recommendations for multi-arm multi-stage trials2016
Professor James Wason
Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions2016
Professor James Wason
A Bayesian adaptive design for biomarker trials with linked treatments2015
Professor James Wason
Evaluation of multisystemic therapy pilot services in Services for Teens Engaging in Problem Sexual Behaviour (STEPS-B): study protocol for a randomized controlled trial2015
Professor James Wason
Multi-armed bandit models for the optimal design of clinical trials: Benefits and challenges2015
Professor James Wason
Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax2015
Professor James Wason
OptGS – An R package for finding near-optimal group-sequential designs.2015
Professor James Wason
Prospective study evaluating the relative sensitivty of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design2015
Professor James Wason
Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule2015
Professor James Wason
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected2015
Professor James Wason
The power of phase II end-points for different possible mechanisms of action of an experimental treatment2015
Professor James Wason
A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials2014
Professor James Wason
Janice Dunn
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.2014
Professor James Wason
Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments2014
Professor James Wason
Confounding in association studies: Month of birth and multiple sclerosis2014
Professor James Wason
Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done?2014
Professor James Wason
Design of telehealth trials - Introducing adaptive approaches2014
Professor James Wason
Recent developments in group-sequential designs2014
Professor James Wason
A "Candidate-Interactome" Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis2013
Professor James Wason
Confounding underlies the apparent month of birth effect in multiple sclerosis2013
Dr David Cottrell
Professor James Wason
Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: Study protocol for a randomised controlled trial2013
Professor James Wason
Planning multi-arm screening studies within the context of a drug development program2013
Professor James Wason
Reducing the average number of patients needed in a phase II trial through novel design2013
Professor James Wason
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma2013
Professor James Wason
Using continuous data on tumour measurements to improve inference in phase II cancer studies2013
Professor James Wason
A General framework for two-stage analysis of genome-wide association studies and its application to case-control studies2012
Professor James Wason
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis2012
Professor James Wason
Identifying combined design and analysis procedures in two-stage trials with a binary end point2012
Professor James Wason
Optimal design of multi-arm multi-stage trials2012
Professor James Wason
Optimal multistage designs for randomised clinical trials with continuous outcomes2012
Professor James Wason
Risk in complex genetics: "all models are wrong but some are useful"2012
Professor James Wason
Stage phase II clinical trials with continuous outcomes2012
Professor James Wason
Accelerated BEP: A phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour2011
Professor James Wason
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis2011
Professor James Wason
Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points2011
Professor James Wason
A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis2010
Professor James Wason
Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia2010
Professor James Wason
What role for genetics in the prediction of multiple sclerosis?2010
Professor James Wason
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor2009